48 related articles for article (PubMed ID: 15041052)
1. Expression of E-cadherin, and CD44s and CD44v6 and its association with prognosis in head and neck cancer.
Kawano T; Nakamura Y; Yanoma S; Kubota A; Furukawa M; Miyagi Y; Tsukuda M
Auris Nasus Larynx; 2004 Mar; 31(1):35-41. PubMed ID: 15041052
[TBL] [Abstract][Full Text] [Related]
2. CD44v6 downregulation as a prognostic factor for distant recurrence in resected stage I lung adenocarcinomas.
Yoshida C; Kadota K; Yamada K; Fujimoto S; Ibuki E; Ishikawa R; Haba R; Yajima T
Clin Exp Med; 2023 Dec; 23(8):5191-5200. PubMed ID: 37743425
[TBL] [Abstract][Full Text] [Related]
3. CD44v6, STn & O-GD2: promising tumor associated antigens paving the way for new targeted cancer therapies.
Lodewijk I; Dueñas M; Paramio JM; Rubio C
Front Immunol; 2023; 14():1272681. PubMed ID: 37854601
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of CD44s, CD44v6, CXCR2, CXCL1, and IL-1β in Benign and Malignant Tumors of Salivary Glands.
Laohavisudhi F; Chunchai T; Ketchaikosol N; Thosaporn W; Chattipakorn N; Chattipakorn SC
Diagnostics (Basel); 2022 May; 12(5):. PubMed ID: 35626430
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of correlation between CD44, radiotherapy response, and survival rate in patients with advanced stage of head and neck squamous cell carcinoma (HNSCC).
Dubey P; Gupta R; Mishra A; Kumar V; Bhadauria S; Bhatt MLB
Cancer Med; 2022 May; 11(9):1937-1947. PubMed ID: 35274800
[TBL] [Abstract][Full Text] [Related]
6. CD44v6 may influence ovarian cancer cell invasion and migration by regulating the NF-κB pathway.
Wang Y; Yang X; Xian S; Zhang L; Cheng Y
Oncol Lett; 2019 Jul; 18(1):298-306. PubMed ID: 31289500
[TBL] [Abstract][Full Text] [Related]
7. The prognostic significance of E-cadherin expression in laryngeal squamous-cell carcinoma: a systematic review.
Re M; Gioacchini FM; Scarpa A; Cassandro C; Tulli M; Cassandro E
Acta Otorhinolaryngol Ital; 2018 Dec; 38(6):504-510. PubMed ID: 30499566
[TBL] [Abstract][Full Text] [Related]
8. Targeting CD44v6 for fluorescence-guided surgery in head and neck squamous cell carcinoma.
Odenthal J; Rijpkema M; Bos D; Wagena E; Croes H; Grenman R; Boerman O; Takes R; Friedl P
Sci Rep; 2018 Jul; 8(1):10467. PubMed ID: 29992954
[TBL] [Abstract][Full Text] [Related]
9. Generation and evaluation of antibody agents for molecular imaging of CD44v6-expressing cancers.
Haylock AK; Nilvebrant J; Mortensen A; Velikyan I; Nestor M; Falk R
Oncotarget; 2017 Sep; 8(39):65152-65170. PubMed ID: 29029420
[TBL] [Abstract][Full Text] [Related]
10. The Importance of CD44 as a Stem Cell Biomarker and Therapeutic Target in Cancer.
Thapa R; Wilson GD
Stem Cells Int; 2016; 2016():2087204. PubMed ID: 27200096
[TBL] [Abstract][Full Text] [Related]
11. In vivo characterization of the novel CD44v6-targeting Fab fragment AbD15179 for molecular imaging of squamous cell carcinoma: a dual-isotope study.
Haylock AK; Spiegelberg D; Nilvebrant J; Sandström K; Nestor M
EJNMMI Res; 2014 Mar; 4(1):11. PubMed ID: 24598405
[TBL] [Abstract][Full Text] [Related]
12. Increased CD44s and decreased CD44v6 RNA expression are associated with better survival in myxofibrosarcoma patients: a pilot study.
Matuschek C; Lehnhardt M; Gerber PA; Poremba C; Hamilton J; Lammering G; Orth K; Budach W; Bojar H; Bölke E; Peiper M
Eur J Med Res; 2014 Feb; 19(1):6. PubMed ID: 24491153
[TBL] [Abstract][Full Text] [Related]
13. Significance of CD44 expression in head and neck cancer: a systemic review and meta-analysis.
Chen J; Zhou J; Lu J; Xiong H; Shi X; Gong L
BMC Cancer; 2014 Jan; 14():15. PubMed ID: 24410905
[TBL] [Abstract][Full Text] [Related]
14. Absent/weak CD44 intensity and positive human papillomavirus (HPV) status in oropharyngeal squamous cell carcinoma indicates a very high survival.
Näsman A; Nordfors C; Grün N; Munck-Wikland E; Ramqvist T; Marklund L; Lindquist D; Dalianis T
Cancer Med; 2013 Aug; 2(4):507-18. PubMed ID: 24156023
[TBL] [Abstract][Full Text] [Related]
15. Expression of COX-2, CD44v6 and CD147 and relationship with invasion and lymph node metastasis in hypopharyngeal squamous cell carcinoma.
Yang Q; Liu Y; Huang Y; Huang D; Li Y; Wu J; Duan M
PLoS One; 2013; 8(9):e71048. PubMed ID: 24019861
[TBL] [Abstract][Full Text] [Related]
16. Correlation of CD44v6 expression with ovarian cancer progression and recurrence.
Shi J; Zhou Z; Di W; Li N
BMC Cancer; 2013 Apr; 13():182. PubMed ID: 23565736
[TBL] [Abstract][Full Text] [Related]
17. Role of the recently identified dysadherin in E-cadherin adhesion molecule downregulation in head and neck cancer.
Georgolios A; Eleftheriadou A; Batistatou A; Charalabopoulos K
Med Oncol; 2012 Sep; 29(3):1463-7. PubMed ID: 22105147
[TBL] [Abstract][Full Text] [Related]
18. Lack of association of cadherin expression and histopathologic type, metastasis, or patient outcome in oropharyngeal squamous cell carcinoma: a tissue microarray study.
Ukpo OC; Thorstad WL; Zhang Q; Lewis JS
Head Neck Pathol; 2012 Mar; 6(1):38-47. PubMed ID: 22072429
[TBL] [Abstract][Full Text] [Related]
19. Lessons from common markers of tumor-initiating cells in solid cancers.
Gires O
Cell Mol Life Sci; 2011 Dec; 68(24):4009-22. PubMed ID: 21786143
[TBL] [Abstract][Full Text] [Related]
20. Role of versican, hyaluronan and CD44 in ovarian cancer metastasis.
Ween MP; Oehler MK; Ricciardelli C
Int J Mol Sci; 2011 Jan; 12(2):1009-29. PubMed ID: 21541039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
